TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Akari Therapeutics ( (AKTX) ) just unveiled an announcement.
On December 8, 2025, Akari Therapeutics, Plc prepared an investor presentation for upcoming conferences and meetings. The presentation, which is part of a Current Report on Form 8-K, is intended to inform stakeholders but is not filed under the Securities Exchange Act of 1934, indicating it is for informational purposes only and not subject to certain legal liabilities.
The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Average Trading Volume: 617,704
Technical Sentiment Signal: Sell
Current Market Cap: $11.06M
For a thorough assessment of AKTX stock, go to TipRanks’ Stock Analysis page.